Age-related Macular Degeneration (AMD): Clinical Program

Phase II Clinical Trial in GA-AMD (Suspended pending funding TBD)

Based upon both the strength of our pre-clinical studies and the positive results from our Phase I/II clinical trial, StemCells, Inc. has initiated the Radiant Study, a Phase II proof-of-concept study using our HuCNS-SC® platform technology for the treatment of advanced dry AMD, also referred to as geographic atrophy (GA). Although we maintain high confidence in the potential of our clinical approach, further enrollment in this study has been suspended while we seek a funding partner.

Phase I/II Trial in GA-AMD (Completed)

In June 2014, based on positive interim results, StemCells, Inc. closed enrollment earlier than planned in its Phase I/II clinical trial to assess the tolerability, safety and preliminary efficacy of subretinal HuCNS-SC transplantation in GA-AMD.

Top-line results for the Phase I/II clinical trial were presented in June 2015. In addition to a favorable safety profile for our HuCNS-SC platform technology, patients demonstrated either stable or improved visual acuity and contrast sensitivity at 6 and 12 months post-transplant. Increased macular volume and foveal thickness was observed in the study eye. Analysis and assessment of changes in RPE defects and GA progression is underway.

I was not ready to give in and say I was going to be blind… I was ready to be a pioneer.”

Roy DeFranco, Phase I/II SCI Clinical Trial Patient

About AMD

According to the Foundation Fighting Blindness, an estimated 10 million people in the United States either have AMD or are at substantial risk for receiving the diagnosis. As the term reflects, AMD results in the degeneration of the central portion of the retina, known as the macula, which leads to the deterioration of central vision. Geographic atrophy, or GA, is the most advanced form of dry AMD, and there is no current effective treatment for any stage of dry AMD.

Learn more about age-related macular degeneration …


Findings from studies performed by StemCells, Inc. and its collaborators on the use of human neural stem cells for the treatment of AMD have been published.

View our publications on age-related macular degeneration …